Back to top
more

Biora Therapeutics, Inc. (BIOR)

(Real Time Quote from BATS)

$0.73 USD

0.73
20,253

0.00 (-0.04%)

Updated May 21, 2024 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BIOR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Biora Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 15 30 88 92 33
Receivables 1 1 1 13 23
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 12 11
Other Current Assets 3 7 9 9 8
Total Current Assets 19 38 98 126 75
Net Property & Equipment 1 2 4 18 16
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 6 6 6 10 11
Deposits & Other Assets 3 6 0 0 0
Total Assets 31 54 109 154 102
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3 4 9 17 16
Current Portion Long-Term Debt 2 0 0 0 0
Current Portion Capital Leases 0 0 0 0 1
Accrued Expenses 17 16 34 55 84
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 41 4 19 0 0
Total Current Liabilities 63 23 62 73 100
Mortgages 0 0 0 3 3
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 44 128 126 159 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 26 5 6 27 82
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 133 156 194 261 186
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 869 744 723 453 283
Retained Earnings -951 -827 -789 -541 -348
Other Equity 0 0 0 0 0
Treasury Stock 19 19 19 19 19
Total Shareholder's Equity -101 -102 -85 -107 -84
Total Liabilities & Shareholder's Equity 31 54 109 154 102
Total Common Equity -101 -102 -85 -107 -84
Shares Outstanding 27.80 8.90 6.50 2.10 NA
Book Value Per Share -3.65 -11.49 -13.07 -50.95 0.00

Fiscal Year End for Biora Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 11 15 13 26 30
Receivables 1 1 1 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 2 3 6 7 6
Total Current Assets 14 19 19 34 37
Net Property & Equipment 1 1 1 1 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 6 6 6 6 6
Deposits & Other Assets 0 3 6 6 6
Total Assets 23 31 35 50 53
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 5 3 4 5 3
Current Portion Long-Term Debt 2 2 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 17 17 24 22 19
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 27 41 41 11 3
Total Current Liabilities 51 63 70 38 25
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 43 44 80 129 128
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 29 4 4 5
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 123 133 153 171 158
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 874 869 836 760 758
Retained Earnings -955 -951 -936 -862 -844
Other Equity 0 0 0 0 0
Treasury Stock 19 19 19 19 19
Total Shareholder's Equity -100 -101 -119 -121 -105
Total Liabilities & Shareholder's Equity 23 31 35 50 53
Total Common Equity -100 -101 -119 -121 -105
Shares Outstanding 35.80 27.80 23.40 11.80 11.80
Book Value Per Share -2.80 -3.65 -5.08 -10.24 -8.90